Literature DB >> 21606591

Role of mTOR in podocyte function and diabetic nephropathy in humans and mice.

Markus Gödel1, Björn Hartleben, Nadja Herbach, Shuya Liu, Stefan Zschiedrich, Shun Lu, Andrea Debreczeni-Mór, Maja T Lindenmeyer, Maria-Pia Rastaldi, Götz Hartleben, Thorsten Wiech, Alessia Fornoni, Robert G Nelson, Matthias Kretzler, Rüdiger Wanke, Hermann Pavenstädt, Dontscho Kerjaschki, Clemens D Cohen, Michael N Hall, Markus A Rüegg, Ken Inoki, Gerd Walz, Tobias B Huber.   

Abstract

Chronic glomerular diseases, associated with renal failure and cardiovascular morbidity, represent a major health issue. However, they remain poorly understood. Here we have reported that tightly controlled mTOR activity was crucial to maintaining glomerular podocyte function, while dysregulation of mTOR facilitated glomerular diseases. Genetic deletion of mTOR complex 1 (mTORC1) in mouse podocytes induced proteinuria and progressive glomerulosclerosis. Furthermore, simultaneous deletion of both mTORC1 and mTORC2 from mouse podocytes aggravated the glomerular lesions, revealing the importance of both mTOR complexes for podocyte homeostasis. In contrast, increased mTOR activity accompanied human diabetic nephropathy, characterized by early glomerular hypertrophy and hyperfiltration. Curtailing mTORC1 signaling in mice by genetically reducing mTORC1 copy number in podocytes prevented glomerulosclerosis and significantly ameliorated the progression of glomerular disease in diabetic nephropathy. These results demonstrate the requirement for tightly balanced mTOR activity in podocyte homeostasis and suggest that mTOR inhibition can protect podocytes and prevent progressive diabetic nephropathy.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21606591      PMCID: PMC3104746          DOI: 10.1172/JCI44774

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  58 in total

1.  Deletion of protein kinase C-beta isoform in vivo reduces renal hypertrophy but not albuminuria in the streptozotocin-induced diabetic mouse model.

Authors:  Matthias Meier; Joon-Keun Park; Daniel Overheu; Torsten Kirsch; Carsten Lindschau; Faikah Gueler; Michael Leitges; Jan Menne; Hermann Haller
Journal:  Diabetes       Date:  2007-02       Impact factor: 9.461

2.  Mammalian target of rapamycin pathway blockade slows progression of diabetic kidney disease in rats.

Authors:  Núria Lloberas; Josep M Cruzado; Marcella Franquesa; Immaculada Herrero-Fresneda; Joan Torras; Gabriela Alperovich; Inés Rama; August Vidal; Josep M Grinyó
Journal:  J Am Soc Nephrol       Date:  2006-04-05       Impact factor: 10.121

3.  Prolonged rapamycin treatment inhibits mTORC2 assembly and Akt/PKB.

Authors:  Dos D Sarbassov; Siraj M Ali; Shomit Sengupta; Joon-Ho Sheen; Peggy P Hsu; Alex F Bagley; Andrew L Markhard; David M Sabatini
Journal:  Mol Cell       Date:  2006-04-06       Impact factor: 17.970

4.  Regulation of cellular growth by the Drosophila target of rapamycin dTOR.

Authors:  H Zhang; J P Stallock; J C Ng; C Reinhard; T P Neufeld
Journal:  Genes Dev       Date:  2000-11-01       Impact factor: 11.361

5.  VEGF inhibition and renal thrombotic microangiopathy.

Authors:  Vera Eremina; J Ashley Jefferson; Jolanta Kowalewska; Howard Hochster; Mark Haas; Joseph Weisstuch; Catherine Richardson; Jeffrey B Kopp; M Golam Kabir; Peter H Backx; Hans-Peter Gerber; Napoleone Ferrara; Laura Barisoni; Charles E Alpers; Susan E Quaggin
Journal:  N Engl J Med       Date:  2008-03-13       Impact factor: 91.245

6.  Renoprotective effects of sirolimus in non-immune initiated focal segmental glomerulosclerosis.

Authors:  Gopala K Rangan; Jason D Coombes
Journal:  Nephrol Dial Transplant       Date:  2007-06-05       Impact factor: 5.992

7.  The Notch pathway in podocytes plays a role in the development of glomerular disease.

Authors:  Thiruvur Niranjan; Bernhard Bielesz; Antje Gruenwald; Manish P Ponda; Jeffrey B Kopp; David B Thomas; Katalin Susztak
Journal:  Nat Med       Date:  2008-03-02       Impact factor: 53.440

8.  High sirolimus levels may induce focal segmental glomerulosclerosis de novo.

Authors:  Emmanuel Letavernier; Patrick Bruneval; Chantal Mandet; Jean-Paul Duong Van Huyen; Marie-Noëlle Péraldi; Imed Helal; Laure-Hélène Noël; Christophe Legendre
Journal:  Clin J Am Soc Nephrol       Date:  2007-02-07       Impact factor: 8.237

9.  A global double-fluorescent Cre reporter mouse.

Authors:  Mandar Deepak Muzumdar; Bosiljka Tasic; Kazunari Miyamichi; Ling Li; Liqun Luo
Journal:  Genesis       Date:  2007-09       Impact factor: 2.487

10.  Improved elucidation of biological processes linked to diabetic nephropathy by single probe-based microarray data analysis.

Authors:  Clemens D Cohen; Maja T Lindenmeyer; Felix Eichinger; Alexander Hahn; Martin Seifert; Anton G Moll; Holger Schmid; Eva Kiss; Elisabeth Gröne; Hermann-Josef Gröne; Matthias Kretzler; Thomas Werner; Peter J Nelson
Journal:  PLoS One       Date:  2008-08-13       Impact factor: 3.240

View more
  256 in total

1.  mTOR in podocyte function: is rapamycin good for diabetic nephropathy?

Authors:  Min-Kan Lu; Xing-Guo Gong; Kun-Liang Guan
Journal:  Cell Cycle       Date:  2011-10-15       Impact factor: 4.534

2.  Growth-dependent podocyte failure causes glomerulosclerosis.

Authors:  Akihiro Fukuda; Mahboob A Chowdhury; Madhusudan P Venkatareddy; Su Q Wang; Ryuzoh Nishizono; Tsukasa Suzuki; Larysa T Wickman; Jocelyn E Wiggins; Timothy Muchayi; Diane Fingar; Kerby A Shedden; Ken Inoki; Roger C Wiggins
Journal:  J Am Soc Nephrol       Date:  2012-07-05       Impact factor: 10.121

3.  mTORC2 Signaling Regulates Nox4-Induced Podocyte Depletion in Diabetes.

Authors:  Stéphanie Eid; Suzan Boutary; Kawthar Braych; Ramzi Sabra; Charbel Massaad; Ahmed Hamdy; Awad Rashid; Sarah Moodad; Karen Block; Yves Gorin; Hanna E Abboud; Assaad A Eid
Journal:  Antioxid Redox Signal       Date:  2016-09-12       Impact factor: 8.401

4.  Niclosamide ethanolamine improves diabetes and diabetic kidney disease in mice.

Authors:  Pengxun Han; Mumin Shao; Lan Guo; Wenjing Wang; Gaofeng Song; Xuewen Yu; Chunlei Zhang; Na Ge; Tiegang Yi; Shunmin Li; Heng Du; Huili Sun
Journal:  Am J Transl Res       Date:  2018-04-15       Impact factor: 4.060

5.  TGFβ acts through PDGFRβ to activate mTORC1 via the Akt/PRAS40 axis and causes glomerular mesangial cell hypertrophy and matrix protein expression.

Authors:  Soumya Maity; Falguni Das; Balakuntalam S Kasinath; Nandini Ghosh-Choudhury; Goutam Ghosh Choudhury
Journal:  J Biol Chem       Date:  2020-07-30       Impact factor: 5.157

6.  microRNA-181a downregulates deptor for TGFβ-induced glomerular mesangial cell hypertrophy and matrix protein expression.

Authors:  Soumya Maity; Amit Bera; Nandini Ghosh-Choudhury; Falguni Das; Balakuntalam S Kasinath; Goutam Ghosh Choudhury
Journal:  Exp Cell Res       Date:  2018-02-01       Impact factor: 3.905

Review 7.  Therapeutic Inhibition of VEGF Signaling and Associated Nephrotoxicities.

Authors:  Chelsea C Estrada; Alejandro Maldonado; Sandeep K Mallipattu
Journal:  J Am Soc Nephrol       Date:  2019-01-14       Impact factor: 10.121

Review 8.  The role of extracellular vesicles in podocyte autophagy in kidney disease.

Authors:  Baichao Sun; Shubo Zhai; Li Zhang; Guangdong Sun
Journal:  J Cell Commun Signal       Date:  2021-02-22       Impact factor: 5.782

9.  Obesity-mediated autophagy insufficiency exacerbates proteinuria-induced tubulointerstitial lesions.

Authors:  Kosuke Yamahara; Shinji Kume; Daisuke Koya; Yuki Tanaka; Yoshikata Morita; Masami Chin-Kanasaki; Hisazumi Araki; Keiji Isshiki; Shin-ichi Araki; Masakazu Haneda; Taiji Matsusaka; Atsunori Kashiwagi; Hiroshi Maegawa; Takashi Uzu
Journal:  J Am Soc Nephrol       Date:  2013-10-03       Impact factor: 10.121

10.  Losartan affects glomerular AKT and mTOR phosphorylation in an experimental model of type 1 diabetic nephropathy.

Authors:  Vasiliki Mavroeidi; Ioannis Petrakis; Kostas Stylianou; Theodora Katsarou; Konstantinos Giannakakis; Kostas Perakis; Eleftheria Vardaki; Spyridon Stratigis; Emmanuel Ganotakis; Stathis Papavasiliou; Eugenios Daphnis
Journal:  J Histochem Cytochem       Date:  2013-03-01       Impact factor: 2.479

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.